Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Summit Therapeutics (SMMT) EBT Margin: 2016-2024

Historic EBT Margin for Summit Therapeutics (SMMT) over the last 3 years, with Dec 2024 value amounting to 729,144.44%.

  • Summit Therapeutics' EBT Margin was N/A to 729,144.44% in Q4 2024 from the same period last year, while for Dec 2024 it was 2,108.65%, marking a year-over-year change of. This contributed to the annual value of 2,701.87% for FY2024, which is 127568.00% down from last year.
  • Per Summit Therapeutics' latest filing, its EBT Margin stood at 729,144.44% for Q4 2024, which was up 29,314.13% from 2,478.89% recorded in Q3 2024.
  • Summit Therapeutics' 5-year EBT Margin high stood at 729,144.44% for Q4 2024, and its period low was -7,700.00% during Q3 2022.
  • For the 2-year period, Summit Therapeutics' EBT Margin averaged around 241,307.78%, with its median value being 2,478.89% (2024).
  • Data for Summit Therapeutics' EBT Margin shows a maximum YoY slumped of 394,131bps (in 2020) over the last 5 years.
  • Quarterly analysis of 3 years shows Summit Therapeutics' EBT Margin stood at -2,296.25% in 2020, then followed by -7,700.00% in 2022, then followed by 729,144.44% in 2024.
  • Its EBT Margin was 729,144.44% in Q4 2024, compared to 2,478.89% in Q3 2024 and -7,700.00% in Q3 2022.